CLEOPATRA Trial: Frontline Pertuzumab for HER2+ MBC
Published Online: Monday, July 15, 2013
For High-Definition, ClickSeveral agents are currently being explored as frontline treatments for patients with HER2-positive metastatic breast cancer. The standard of care for these patients was disrupted in 2012, when the FDA approved a frontline regimen of pertuzumab, trastuzumab, and docetaxel.
This approval was based on findings from the phase III CLEOPATRA trial that randomized 808 women to trastuzumab, docetaxel, and pertuzumab or trastuzumab, docetaxel, and placebo. The addition of pertuzumab results in a dual blockade of the HER2 extracellular domain, which resulted in an impressive prolongation in both progression-free survival and overall survival, notes Andrew D. Seidman, MD. This three-drug regimen has become the standard of care in this setting, Seidman adds.
This switch in the standard of care complicates the interpretation of ongoing trial results, such as the phase III MARIANNE trial. In this trial, T-DM1 with or without pertuzumab is being compared to trastuzumab and a taxane. As a result, a cross trial comparison of the MARIANNE and CLEOPATRA trials will likely be necessary, Seidman notes. If these approaches are similar in terms of efficacy, their side effect profiles will be the deciding factor in how they are prescribed.
If they have similar efficacy, the frontline regimen utilized may also be impacted by the costs associated with treatment, Hope S. Rugo, MD believes. Moreover, she notes, there is a lack of data to support that T-DM1 is an effective treatment for brain metastases. Along these lines, local options are available for patients with brain metastases but, overall, there are few effective options for these patients, Joyce A. O'Shaughnessy, MD, adds.
A larger questions, believes Sara Hurvitz, MD, is the impact these trials and concerns will play on the overall sequencing of agents in the second- and third-line for patients with metastatic breast cancer.
View More From This Discussion
The standard of care for patients with HER2-positive metastatic breast cancer was disrupted in 2012, when the FDA approved a frontline regimen of pertuzumab, trastuzumab, and docetaxel. In this segment, the panelists discuss the implications of this approval on the interpretation of ongoing clinical trials.
View Episode >>>
View Episode >>>
Sara Hurvitz, MDAssistant Professor & Director,
Hematology/Oncology Breast Cancer Program, UCLA's Jonsson Comprehensive Cancer Center, Los Angeles, California
Joyce A. O’Shaughnessy, MDCo-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology, PA/US Oncology,
Edith A. Perez, MDDeputy Director of the Mayo Clinic Cancer Center, Director of the Breast Cancer Translational Genomics Program and the Breast Program at Mayo Clinic,
Hope S. Rugo, MDProfessor of Medicine and Director of the Breast Oncology, Clinical Trials, and Education Program, University of California San Francisco Comprehensive Cancer Center, San Francisco, California
Andrew D. Seidman, MDProfessor of Medicine, Weill Cornell Cancer Center, Attending Physician at Memorial Sloan Kettering Cancer Center,
New York, New York
Most Popular Right Now
Online CME Activities
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.